Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System

BACKGROUND: Evidence on mortality risks associated with MS-immunotherapies during the SARS-CoV2 pandemic derived thus far mainly from single country experiences. OBJECTIVE: In this analysis, we aim to determine the frequency of COVID-19 associated fatality reports of patients receiving an MS-immunot...

Descripción completa

Detalles Bibliográficos
Autores principales: Pistor, Maximilian, Hoepner, Robert, Hoepner, Andreas G.F., Lin, Yanan, Jung, Simon, Bassetti, Claudio L., Chan, Andrew, Salmen, Anke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551667/
https://www.ncbi.nlm.nih.gov/pubmed/36237201
http://dx.doi.org/10.1177/17562864221129383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551667/
https://www.ncbi.nlm.nih.gov/pubmed/36237201
http://dx.doi.org/10.1177/17562864221129383

Ejemplares similares